September 05, 2017
Cellecta now offers the mouse Thy1.1 gene (Thymus Cell Antigen 1.1, CD90.1) as a marker in custom CRISPR, RNAi, and cDNA constructsThy1 genes express small, almost peptide-like T-cell glycooprotein expressed by thymocytes, hematopoietic stem cells, some fibroblast and muscle cells in most mammals. These...
Read More April 07, 2016
Last year, Cellecta received a Phase 1 NIH SBIR grant to develop validated single guide RNA (sgRNA). The initial study was designed to investigate an approach to optimize CRISPR sgRNA to improve the efficiency of CRISPR knockout.The 5'-end of the CRISPR sgRNA contains 20 nucleotides specific to the gene targeted...
Read More July 22, 2015
Cellecta received a Phase I NIH SBIR Grant to develop CRISPR guide RNAs (gRNAs or sgRNAs) for human and mouse genes and then use these to build a knockout library targeting 6,500 key disease-related genes in major signal transduction pathways.Targeting a gene for knockout using CRISPR requires a short strand of...
Read More March 12, 2015
The previous blog post " Two-Vector CRISPR System Is Better Approach for Knockout Screens" discussed the advantages of expressing the Cas9 nuclease on a vector separate from the one used for the guide RNAs (sgRNA)—a two-vector CRISPR system—when using the system for complex pooled loss-of-function screens. In...
Read More November 26, 2014
Since our introduction of the All-in-One CRISPR-Cas9 lentiviral system in the Spring, we have done a bit more work and moved forward with a two-vector system for our pooled libraries of sgRNA expression constructs. If the All-in-One CRISPR-Cas9 vector works well—which it does—why, you might wonder, would we...
Read More February 26, 2014
The ability to identify and quantify the size of clonal cell populations produced by each cell in a founder population offers researchers a powerful tool for understanding how groups cells grow and proliferate in all sorts of conditions. This sort of clonal cell tracking enables cell biologists,...
Read More February 11, 2013
At Cellecta, we have relied primarily on lentiviral vectors to develop our RNAi genetic screening technology. The broad tropism of lentivirus-based plasmids packaged into VSV-g pseudotyped viral particles provides a very convenient vector system to introduce and stably express shRNA expression...
Read More